RENEW 2Cagrilintide for Weight Management in Overweight or Obesity with Type 2 Diabetes

This clinical trial investigates whether a new medicine called cagrilintide can help people who are overweight or have obesity, as well as type 2 diabetes, to lose weight. This study is important because managing weight is a crucial part of controlling type 2 diabetes, which can be challenging for many people. Cagrilintide is still under study and not yet available for doctors to prescribe. By exploring its effectiveness and safety, this research aims to contribute to potential new treatments that could support better health outcomes for those struggling with these conditions. In the study, participants will receive either cagrilintide or a placebo, which is a substance with no active medication. The assignment to either the medicine or placebo is random, but participants have a higher chance, specifically two times more likely, of receiving cagrilintide. The medication or placebo will be administered, and participants will be monitored for any changes in body weight and possible side effects. The entire duration of the study for each participant is approximately one year and six months, allowing researchers to gather comprehensive data on the long-term effects and safety of cagrilintide.